Scholars@Duke
Michaela Ann Dinan

Michaela Ann Dinan

Adjunct Associate Professor in Population Health Sciences
Population Health Sciences
michaela.dinan@duke.edu
Duke Box 104023, Durham, NC 27710
60 College St, PO Box 208034, New Haven, CT 06520

Scholarly Works - Conferences

Treatment exposure-based risk-stratification for care of survivors of childhood cancer: a report from the childhood cancer survivor study.

Conference J Natl Cancer Inst · December 1, 2025 BACKGROUND: Treatment exposure-based risk-stratification of long-term cancer survivors may help inform health care in survivorship clinics. We used the large, diverse population of the Childhood Cancer Survivor Study to test a modified, exposure-based stra ... Full text Link to item Cite

Risk and predictors of late second primary malignancies in long-term breast, prostate, colon, and rectal cancer survivors

Conference Journal of Clinical Oncology · January 1, 2025 Background: In older, long-term (5-year) cancer survivors, mortality risks from aging and treatment-related effects may surpass those of their index cancer. Second primary malignancies (SPMs) occurring 5-10 years post-diagnosis are understudied in older pa ... Full text Cite

Trends in new and persistent opioid use in older adults with and without cancer.

Conference J Natl Cancer Inst · February 8, 2024 BACKGROUND: The impact of ongoing efforts to decrease opioid use on patients with cancer remains undefined. Our objective was to determine trends in new and additional opioid use in patients with and without cancer. METHODS: This retrospective cohort study ... Full text Link to item Cite

Abstract P4-09-08: Shared-patient physician networks and their impact on the uptake of genomic testing in early-stage breast cancer

Conference Cancer Research · February 15, 2019 AbstractBackground: Oncotype DX (ODX) or 21-gene recurrence score genomic testing is used to stratify risk and determine appropriate treatment in women with early-stage breast cancer (BC). Diffusion of ODX b ... Full text Cite

Nationwide utilization and costs of targeted anti-cancer drugs for elderly patients with solid tumors in the United States, 2004-2015.

Conference Journal of Clinical Oncology · October 20, 2018 23 Background: Studies of patients age < 65 suggest large increases in utilization and costs of targeted anti-cancer drugs (TADs). However, use and costs of TADs in patients age 65+ have not been examined in a national sample. ... Full text Cite

Androgen deprivation therapy (ADT) and cardiovascular mortality (CVD) in men with early-stage prostate cancer (PC) receiving curative radiation therapy (RT).

Conference Journal of Clinical Oncology · March 1, 2018 127 Background: Combined with RT, ADT is a highly effective and utilized treatment for men with localized PC, but some studies suggest that use of ADT leads to increased CVD. We explored the association between ADT and CVD in men ... Full text Cite

Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma.

Conference Journal of Clinical Oncology · February 20, 2018 415 Background: Several immunotherapies recently have been approved for the treatment of locally advanced or metastatic bladder cancer that is prevalent in older adults. Utilization patterns in Medicare patients have not been exa ... Full text Cite

Use of Whole Brain Radiation Therapy and Immune Checkpoint Inhibition in the Management of Brain Metastases

Conference International Journal of Radiation Oncology*Biology*Physics · October 2017 Full text Cite

Chemotherapy costs associated with receipt of the adoption of oncotype DX in early-stage breast cancer within the SEER-Medicare population.

Conference Journal of Clinical Oncology · March 1, 2016 32 Background: The Oncotype DX (ODX) multigene assay has been previously suggested to result in an overall reduction in the use of adjuvant chemotherapy and associated costs for women with early stage, estrogen receptor (ER)-posi ... Full text Cite

Longitudinal Trends in Costs of Palliative Radiation for Metastatic Prostate Cancer.

Conference J Palliat Med · November 2015 BACKGROUND: In recent years, palliative treatment of prostate cancer metastases has been characterized by the use of more complex radiation treatment, despite a lack of evidence demonstrating a clinical benefit of these technologies in the palliative setti ... Full text Link to item Cite

Relative Incidence of Uterine Sarcoma and Surgical Treatments for Fibroids

Conference ANNALS OF SURGICAL ONCOLOGY · February 1, 2015 Link to item Cite